Leucovorin in autism
Cerebral folate deficiency is a condition in which the brain can be short of folate despite normal blood levels. Leucovorin (folinic acid) has been studied as a way of bypassing a blocked folate transporter. The evidence that it treats autism is limited. It is not NICE guidance, and it is not a treatment for core autistic traits.
What is actually known
Folate receptor autoantibodies (FRAA) have been reported at high rates in selected research cohorts. That is not the same as saying many autistic children in an unselected UK clinic have “gatekeepers” blocked and a brain “running on empty.” True cerebral folate deficiency due to a confirmed FOLR1 gene variant (CFD-FOLR1) is rare.
A blocked transporter, where it is demonstrated in a specific child, is a biochemical finding. It does not establish that folate shortage causes core autistic traits, and it does not support a benefits list as if leucovorin were a targeted autism treatment.
Why leucovorin is discussed at all
Leucovorin (folinic acid) can use the reduced folate carrier, a different route from folic acid. Small clinical trials have reported changes in some children, including some who tested FRAA-positive. FRAA testing is not an NHS test. Remaining trials are small. This is not a settled treatment pathway.
What has changed since this page was first written
The largest randomised trial of leucovorin for autism (Panda et al.) has been retracted. Remaining trials are small. Leucovorin is not a cure for autism, and it should not be presented as a targeted, promising treatment on the strength of that limited evidence.
In September 2025 the US FDA announced it would approve leucovorin for cerebral folate deficiency associated with autism. On 10 March 2026 it instead approved expanded use of Wellcovorin (leucovorin calcium) tablets only for cerebral folate deficiency in patients with a confirmed FOLR1 gene variant (CFD-FOLR1) — not for autism. That is not the same as NICE recommending it for autism in the UK.
The second edition of Leucovorin for Autism: A Guide for Parents and Professionals explains the retracted Panda trial, why the evidence is limited, and what remains uncertain. It is not a treatment manual and not NICE guidance.
See also: the March 2026 note on the Panda retraction.